Administrative Core

行政核心

基本信息

批准号：
7904450
负责人：
Rama Rao Amara
金额：
$ 39.92万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-06-01 至 2013-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7904450
关键词：
Acquired Immunodeficiency Syndrome Adenoviruses Adherence Animal Model Annual Reports Antigens Antiviral Agents Avidity B-Lymphocytes Binding Budgets CCR5 gene CD4 Positive T Lymphocytes Cause of Death Cells Clinical Consultations Country Cytotoxic T-Lymphocytes DNA DNA Vaccines Data Analyses Dendritic Cells Developed Countries Development Electroporation Ensure Failure Generations Goals HIV Vaccine Trials Network HIV vaccine HIV-1 HIV/SIV vaccine Home environment Human Immunization Individual Infection Infection Control Intellectual Property Laboratories Leadership Legal patent Life Lymphocytic choriomeningitis virus Lymphoid Tissue Macaca Mediation Memory Modeling Modified Vaccinia Virus Ankara Pathway interactions Peptide Vaccines Peptides Pharmaceutical Preparations Phase Phenotype Play Publications Publishing Resources Role SIV Safety Sirolimus Solutions T cell response T memory cell T-Cell Development T-Lymphocyte TNFRSF5 gene Testing Toxic effect Treatment Protocols United States United States National Institutes of Health Vaccines Viral Viral Vector Virus Virus Diseases base cost data management data sharing design drug resistant virus immunogenicity improved improved functioning mTOR protein meetings memory CD4 T lymphocyte novel vaccines preclinical study programs prototype receptor repository response vector-based vaccine

项目摘要

The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the fourth leading cause of death worldwide. Development of an effective vaccine against HIV/AIDS is the long term solution to this problem. The failure of Merck's adenovirus type 5 (Ad5) based HIV-1 clade B vaccine in humans that is designed to elicit primarily antiviral T cells strongly suggests the need to develop novel vaccine approaches that generate high levels of anti-viral T cells with improved function as well as protective Ab. The goal of this HIVRAD is to generate high levels of broadly cross-reactive antiviral T cells with enhanced proliferative/protective phenotype and high avidity antiviral binding Ab by targeting CD40 and mTOR (mammalian target of rapamycin) pathways. The overall goal of this administrative core is to provide coordination between projects 1 and 2, and core B, and help with data management and data analyses. This Administrative Core has the following six specific aims: (1) Provide overall coordination for the Program. (2) Provide data management and statistical support. (3) Provide logistical support for intellectual property filings and negotiations. (4) Assist with publications. (5) Maintain budgets and fiscal oversight. (6) Provide vaccines and peptides

由 HIV-1 引起的获得性免疫缺陷综合症 (AIDS) 是第四大死因全世界。开发有效的艾滋病毒/艾滋病疫苗是解决这一问题的长期方案。这默克公司基于 HIV-1 进化枝 B 的 5 型腺病毒 (Ad5) 疫苗在人体中失败，该疫苗旨在引发主要抗病毒 T 细胞强烈表明需要开发新的疫苗方法，以产生高具有改善功能和保护性抗体的抗病毒 T 细胞水平。 HIVRAD 的目标是产生高水平的广泛交叉反应的抗病毒 T 细胞，具有增强的增殖/保护表型以及通过靶向 CD40 和 mTOR（哺乳动物雷帕霉素靶点）途径的高亲和力抗病毒结合抗体。该管理核心的总体目标是在项目 1 和 2 以及核心 B 之间提供协调，并帮助进行数据管理和数据分析。该行政核心有以下六项具体内容：目标：（一）统筹协调本计划。（2）提供数据管理和统计支持。（三）为知识产权备案、谈判提供后勤保障。（四）协助出版工作。 (5) 维持预算和财政监督。（六）提供疫苗和多肽